Field Medical Shares Groundbreaking Six-Month Data at VT Symposium 2025 on Innovative Therapy for Ventricular Tachycardia

Field Medical Presents Innovative Data at VT Symposium 2025

Field Medical, Inc., a pioneering entity in pulsed field ablation (PFA) technology aimed at treating ventricular tachycardia (VT), recently announced its participation in the prestigious 20th Annual International VT Symposium. The event takes place in Philadelphia from October 10 to 11, 2025, marking a significant opportunity for the company to highlight its advancements in cardiac care.

The symposium will feature three key sessions led by Field Medical, where the company will unveil its first six-month clinical results from the FieldForce™ Ablation System. This state-of-the-art platform is the first specifically designed for focal contact force PFA for VT, bringing new hope to patients suffering from this challenging condition. In addition to these initial results, Field Medical will conduct a recorded live case and present findings from its preclinical translational research.

In an exciting lineup of presentations, Dr. Vivek Reddy will showcase outcomes from the late-breaking clinical trial competition, discussing ‘High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia’ on Friday, October 10. This presentation will provide insight into the final six-month results of the inaugural study involving human subjects. On Saturday, Dr. Cory Tschabrunn will share insights from the chronic infarct pig model, further elaborating on the innovative use of high-voltage PFA for VT.

Moreover, Dr. Reddy will demonstrate real-time applications of their technology in treating VT during the recorded live case presentation titled ‘Image Guided High Voltage VT Ablation’. This showcase emphasizes the importance of clinical breakthroughs and mirrors Field Medical's commitment to advancing research that effectively tackles ventricular arrhythmias.

Mark Wisniewski, CEO of Field Medical, expressed the significance of the symposium as a platform for promoting clinical science. Wisniewski stated, “We are excited to present our groundbreaking data, which underscores the urgent need for innovative solutions to support VT patients. Our six-month results reveal the potential of our PFA technology in addressing these complex arrhythmias, highlighting our unique approach and robust results.